Do I need an in-person exam for Topamax in Illinois?

If you’re struggling with binge eating disorder (BED), you’ve likely wondered whether you can access treatment from the comfort of your home. The short answer is yes—telehealth has opened new doors for individuals seeking help for BED, including access to prescription medications that can support recovery. But with evolving federal and state regulations, understanding what’s legal, safe, and accessible can feel overwhelming.

This comprehensive guide breaks down everything you need to know about getting BED medication through telehealth in 2026, from regulatory requirements to safety considerations.

Understanding Binge Eating Disorder and Treatment Options

Binge Eating Disorder is the most common eating disorder in the United States, characterized by recurrent episodes of eating large quantities of food in a short period, accompanied by a sense of loss of control. Unlike bulimia, BED doesn’t involve purging behaviors. According to DSM-5 criteria, a diagnosis requires binge eating episodes at least once weekly for three months, along with marked distress about the behavior.

Treatment for BED typically involves a combination of psychotherapy (particularly cognitive-behavioral therapy), nutritional counseling, and in some cases, medication. While only one medication—lisdexamfetamine (Vyvanse), a controlled stimulant—has FDA approval specifically for BED, healthcare providers commonly prescribe other medications off-label to help manage symptoms and reduce binge frequency.

Two medications frequently used off-label for BED are topiramate (Topamax) and bupropion (Wellbutrin). Both are non-controlled substances, which significantly impacts their accessibility via telehealth.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Prescribing Rules: What You Need to Know

The Ryan Haight Act and Non-Controlled Medications

At the federal level, the Ryan Haight Act of 2008 established strict requirements for prescribing controlled substances via telemedicine, typically requiring an in-person medical evaluation before prescribing. However—and this is crucial—this law does not apply to non-controlled medications like Topamax or Wellbutrin.

This means that from a federal standpoint, healthcare providers can legally prescribe these BED medications via telehealth without any mandatory in-person visit, as long as they follow standard medical practices and are licensed in your state.

Current DEA Telehealth Flexibilities (Through December 2026)

During the COVID-19 pandemic, the DEA implemented emergency rules allowing controlled substance prescribing via telehealth without an initial in-person visit. Good news: these flexibilities have been extended through December 31, 2026, giving the DEA time to finalize permanent regulations.

While this primarily affects controlled medications (not the non-controlled BED treatments we’re discussing), it reflects the federal government’s ongoing commitment to telehealth access. For patients seeking non-controlled medications for BED, the regulatory environment remains open and accessible.

State-by-State Telehealth Prescribing Requirements

While federal law sets the baseline, individual states can add their own requirements. Here’s what you need to know about telehealth prescribing rules across different states:

States with No In-Person Requirements

California leads in telehealth accessibility. Recent legislation (AB 1503, 2025) explicitly recognized asynchronous telehealth evaluations as valid for establishing a patient-provider relationship. Providers can prescribe non-controlled medications after a video visit or even a comprehensive online questionnaire, as long as it meets the standard of care.

New York similarly places no in-person requirement on non-controlled prescriptions. While New York implemented rules in May 2025 requiring in-person exams for controlled substances once federal waivers end, these restrictions don’t apply to medications like Topamax or Wellbutrin.

Texas allows telehealth prescribing for non-controlled medications without in-person visits. Nurse practitioners and physician assistants can prescribe these medications under their collaborative agreements with physicians.

Other states with no in-person requirements for non-controlled telehealth prescriptions include Delaware, Florida, Michigan, Wisconsin, and South Carolina.

States Requiring Periodic In-Person Follow-Up

A few states require periodic in-person visits for ongoing telehealth care:

Alabama requires an in-person visit within 12 months if a patient receives more than four telehealth visits for the same condition. Importantly, this visit can be satisfied by any collaborating provider in the practice, not necessarily the telehealth prescriber.

Georgia requires providers to attempt an annual in-person examination for patients receiving ongoing telemedicine care, though initial evaluations can be conducted via telehealth if the technology used is equivalent to an in-person exam.

New Hampshire recently modernized its telehealth laws (SB 252, effective August 2025), removing most barriers but maintaining a 12-month in-person follow-up requirement for patients on Schedule II-IV controlled substances. For non-controlled BED medications, this requirement doesn’t apply.

Provider Licensing: A Critical Requirement

Regardless of state-specific telehealth rules, one universal requirement remains: your provider must be licensed in the state where you’re located at the time of the consultation. This applies whether you’re seeing a physician, nurse practitioner, or physician assistant.

Interstate medical licensure compacts and telehealth-specific licenses have made this easier for providers, but always verify that your telehealth provider is properly licensed for your state.

Who Can Prescribe BED Medications via Telehealth?

Physicians and Physician Assistants

Medical doctors (MDs) and doctors of osteopathic medicine (DOs) can prescribe Topamax and Wellbutrin via telehealth in all 50 states, subject to state telehealth regulations.

Physician assistants (PAs) can also prescribe these medications in every state, though they universally require a collaborative or supervisory agreement with a physician. This behind-the-scenes requirement typically doesn’t affect patient care—you’ll receive the same quality of service, though both names may appear on your prescription.

Nurse Practitioners: Expanding Independence

The landscape for nurse practitioner (NP) prescribing has evolved dramatically in recent years. As of 2026, approximately 34 states plus Washington, D.C. grant NPs full practice authority, meaning they can evaluate, diagnose, and prescribe medications independently without physician oversight.

Recent additions to this list include:

• Michigan (Public Act 47 of 2023, implemented 2025)
• Wisconsin (APRN Modernization Act, August 2025)
• Kansas and Louisiana (2023-2024 legislative changes)

In these states, an NP can provide complete BED care via telehealth, from initial evaluation through ongoing medication management, without any physician involvement required.

In states without full practice authority—such as Texas, Florida, Georgia, and Alabama—NPs must work under collaborative agreements with physicians. This doesn’t mean lower-quality care; it’s simply a regulatory framework. Your NP can still prescribe Topamax or Wellbutrin for BED, but they do so under a formal agreement with a supervising physician.

A few states (Alabama and South Carolina) have discussed NP independence legislation in 2025, but these bills haven’t been enacted yet. If you’re in one of these states, expect NPs to continue working within collaborative practice agreements for now.

Medications Commonly Prescribed for BED via Telehealth

Topiramate (Topamax)

Classification: Non-controlled prescription medication
FDA-Approved Uses: Epilepsy, migraine prevention
BED Use: Off-label

Topiramate has shown promise in reducing binge eating frequency and promoting weight loss in clinical studies. Providers typically start at low doses (25-50mg) and gradually increase to minimize side effects.

Key Safety Considerations:

• Pregnancy Risk: Topiramate is associated with significant birth defect risks, including cleft palate. Women of childbearing age should use effective contraception.
• Cognitive Effects: Some patients experience ‘brain fog’ or word-finding difficulties, especially at higher doses
• Titration Required: Gradual dose increases and decreases are essential to minimize side effects and prevent seizure risk upon discontinuation
• Monitoring: Regular weight checks, metabolic panels, and cognitive assessments

Typical Telehealth Supply: Providers can prescribe up to 90-day supplies with refills, though they’ll likely start with shorter supplies during initial titration.

Bupropion (Wellbutrin)

Classification: Non-controlled prescription medication
FDA-Approved Uses: Major depressive disorder, seasonal affective disorder, smoking cessation
BED Use: Off-label

Bupropion’s mechanism—affecting dopamine and norepinephrine—may help reduce binge eating urges and improve mood, particularly in patients with comorbid depression.

Key Safety Considerations:

• Contraindications: Absolute contraindication in patients with current or past eating disorders involving purging (bulimia or anorexia) due to increased seizure risk. Providers should carefully screen for this during telehealth evaluations.
• Seizure Risk: Also contraindicated in seizure disorders, and risk increases with alcohol use or abrupt benzodiazepine discontinuation
• Black Box Warning: Like all antidepressants, bupropion carries a warning about increased suicidal thoughts in patients under 25. Close monitoring is essential, especially in the first few months.
• Monitoring: Blood pressure checks (bupropion can elevate BP), mood monitoring, and alcohol use screening

Typical Telehealth Supply: Up to 90-day supplies with refills for up to one year, though providers typically schedule regular follow-ups to monitor response.

Why Not Vyvanse?

You might wonder why telehealth providers don’t typically prescribe Vyvanse (lisdexamfetamine), the only FDA-approved medication for BED. The answer lies in its classification as a Schedule II controlled substance.

Under current DEA rules, prescribing controlled substances via telehealth remains under temporary emergency provisions expiring December 31, 2026. Many reputable telehealth platforms avoid prescribing Schedule II stimulants due to regulatory uncertainty, abuse potential, and heightened scrutiny following enforcement actions against providers who inappropriately prescribed controlled substances online.

If your healthcare provider determines you need Vyvanse for BED, they’ll likely refer you to an in-person specialist or require an in-person evaluation before prescribing via telehealth (where state law allows).

The Telehealth Evaluation Process: What to Expect

Initial Consultation

A thorough telehealth evaluation for BED typically takes 30-60 minutes—significantly longer than a quick questionnaire. During this visit, your provider will:

Assess BED Criteria: Expect detailed questions about your eating patterns, including:

• Frequency of binge episodes (at least weekly for three months)
• Amount of food consumed during binges
• Sense of loss of control during episodes
• Associated distress and emotional triggers
• Absence of compensatory behaviors (purging, excessive exercise)

Review Medical History: Your provider will ask about:

• Previous eating disorder diagnoses or treatment
• Current medications and supplements
• Mental health history (depression, anxiety, trauma)
• Substance use, including alcohol
• Medical conditions (seizures, liver/kidney disease, cardiovascular issues)
• Pregnancy status or plans

Screen for Contraindications: For medications like bupropion and topiramate, providers must carefully screen for conditions that would make these medications unsafe, such as:

• History of purging-type eating disorders (for bupropion)
• Seizure disorders
• Pregnancy or inadequate contraception (for topiramate)
• Kidney stones (topiramate increases risk)

Verify Identity and Location: Don’t be surprised when your provider asks for ID and confirms your physical location. Many states require this verification to ensure proper licensing and prevent fraud.

Documentation and Consent

Legitimate telehealth providers maintain comprehensive electronic health records, just as they would for in-person visits. You’ll review and sign:

• Telehealth Consent: Explaining what telehealth can and cannot do, privacy protections, and any limitations on prescribing
• Medication Consent: Acknowledging off-label use (for BED), potential side effects, and contraindications
• HIPAA Authorization: Protecting your health information privacy

This documentation creates the same legal and clinical foundation as an in-person visit.

Follow-Up Schedule

Starting a new medication for BED requires ongoing monitoring. A typical telehealth treatment plan includes:

• Week 2-4: Initial follow-up to assess tolerance, side effects, and early response
• Months 1-3: Monthly check-ins during dose titration and stabilization
• Months 3+: Every 1-3 months for ongoing management, adjusting based on progress

Some states require annual in-person visits for continued telehealth care. Your provider will inform you of any such requirements and help coordinate care accordingly.

Safety and Quality: Choosing a Reputable Telehealth Provider

The telehealth industry has grown exponentially, but not all providers maintain the same standards. High-profile enforcement actions—including the 2024 federal indictment of executives at a telehealth company for recklessly prescribing Adderall—underscore the importance of choosing carefully.

Red Flags to Watch For

Prescription Guarantees: Be wary of services that promise medications before evaluation. Legitimate providers assess first, then determine appropriate treatment, which may or may not include medication.

Minimal Evaluation: If your consultation takes less than 10 minutes and involves only a few yes/no questions, that’s a significant red flag. Proper BED evaluation requires comprehensive assessment.

No Discussion of Alternatives: Reputable providers discuss the full range of BED treatments, including psychotherapy, nutritional counseling, and support groups. Medication is one tool, not the only option.

Direct Medication Sales: Legitimate telehealth services send prescriptions to licensed pharmacies (retail or mail-order). If a provider wants to sell you medication directly from their own warehouse, avoid them.

Lack of Follow-Up: One-and-done prescribing without scheduled follow-up indicates poor clinical practice and potential regulatory violations.

Green Flags: What Good Telehealth Looks Like

Thorough Screening: Comprehensive intake questionnaires, detailed medical history review, and sometimes standardized assessments (like the Eating Disorder Examination Questionnaire)

Licensed Providers: Clear information about provider credentials, licensing states, and ability to verify their licenses through state medical boards

Transparent Pricing: Upfront costs for consultations and follow-ups, with clear information about insurance acceptance

Multidisciplinary Approach: Discussion of therapy, nutrition, and lifestyle modifications alongside medication options

Regular Monitoring: Scheduled follow-up appointments, ability to message providers between visits, and clear protocols for emergencies

Privacy Protections: HIPAA-compliant platforms with secure video and messaging

Klarity Health: A Patient-Centered Approach

When seeking BED treatment via telehealth, platforms like Klarity Health prioritize both accessibility and clinical excellence. Klarity connects patients with licensed mental health providers who specialize in eating disorders, offering:

• Flexible Scheduling: Provider availability that works with your schedule, often including evening and weekend appointments
• Transparent Pricing: Clear upfront costs, with options for both insurance coverage and affordable self-pay rates
• Comprehensive Care: Providers who address BED holistically, combining medication management when appropriate with therapy referrals and ongoing support

This combination of convenience, transparency, and clinical rigor reflects the best of what telehealth can offer.

Insurance Coverage and Cost Considerations

Telehealth Parity Laws

Most states now have telehealth parity laws requiring insurance companies to cover telehealth services at the same rate as in-person visits. However, coverage specifics vary:

Medicare: Extended telehealth coverage through 2026, including mental health services, though some geographical and originating site restrictions may apply

Medicaid: Coverage varies by state; many states expanded telehealth coverage during the pandemic and have maintained these expansions

Private Insurance: Generally required to cover telehealth under parity laws, but check your specific plan’s telehealth provisions

Out-of-Pocket Costs

If paying out-of-pocket or if your insurance doesn’t cover telehealth:

Initial Consultation: Typically $150-300
Follow-Up Visits: Usually $75-150
Medication Costs:

• Topiramate (generic): $10-30/month without insurance
• Bupropion (generic): $10-25/month without insurance

Many telehealth platforms, including Klarity Health, offer competitive self-pay rates and transparent pricing, making treatment accessible even without insurance coverage.

Who May Not Be Suitable for Telehealth BED Treatment

While telehealth expands access dramatically, certain situations require in-person evaluation or more intensive care:

Medical Complexity

Severe Medical Instability: If BED has resulted in urgent health complications (severe electrolyte imbalances, uncontrolled diabetes, cardiovascular issues), in-person medical evaluation is essential.

Need for Physical Examination: Certain symptoms may require hands-on physical assessment that telehealth cannot provide.

Clinical Contraindications

High-Risk Medication Candidates:

• Active purging behaviors (contraindication for bupropion)
• Uncontrolled seizure disorder
• Pregnancy or inadequate contraception (for topiramate)
• Severe kidney disease
• Active substance use disorder

Severe Comorbid Conditions:

• Active suicidal ideation requiring crisis intervention
• Severe depression not responsive to outpatient care
• Psychotic symptoms
• Other eating disorder subtypes requiring specialized treatment

Need for Controlled Substances

If evaluation suggests that FDA-approved Vyvanse would be most appropriate, current telehealth limitations on controlled substances may require in-person evaluation or referral to a specialist.

Prescription Monitoring Programs (PMPs)

You might wonder whether your telehealth provider will check prescription monitoring databases before prescribing BED medications.

Legal Requirements: Most states mandate PMP checks before prescribing controlled substances (Schedule II-V). However, since topiramate and bupropion are not controlled, these mandatory checks typically don’t apply.

Clinical Practice: Despite no legal requirement, many conscientious providers still review PMPs or medication histories as a safety check—for example, to ensure you’re not already on another bupropion-containing medication (some smoking cessation products) or to identify potential drug interactions.

This practice reflects good clinical care rather than legal obligation and shouldn’t cause concern—it’s part of ensuring your safety.

Looking Ahead: The Future of Telehealth for BED

Regulatory Landscape

The DEA continues working on permanent telehealth prescribing rules, with a final decision expected before the current emergency provisions expire on December 31, 2026. These changes will primarily affect controlled substance prescribing and shouldn’t impact access to non-controlled BED medications.

Several states continue expanding NP and PA practice authority, which will further improve access to telehealth providers who can independently manage BED treatment.

Technology Advances

Emerging technologies promise to enhance telehealth BED care:

Remote Monitoring: Wearable devices and apps that track eating patterns, mood, and physical activity
AI-Assisted Screening: Tools that help identify BED earlier and more accurately
Integration with Therapy Platforms: Coordinated care between medication management and digital therapy programs

Research and Evidence

Ongoing studies continue to evaluate the effectiveness of telehealth-delivered BED treatment. Early evidence suggests that outcomes for medication management via telehealth are comparable to in-person care when proper protocols are followed, with the added benefits of improved access and reduced barriers to seeking help.

Practical Steps: Getting Started with Telehealth BED Treatment

1. Prepare for Your Consultation

Gather Information:

• List of current medications and supplements
• Medical history, including any previous eating disorder treatment
• Insurance information (if applicable)
• List of questions for your provider

Track Your Symptoms:

• Frequency of binge eating episodes
• Triggers and patterns
• Associated emotions
• Impact on daily functioning

2. Choose Your Platform

Research telehealth providers with expertise in eating disorders. Look for:

• Licensed providers in your state
• Specialized eating disorder experience
• Transparent pricing and insurance acceptance
• Positive patient reviews
• Comprehensive care approach

3. Schedule Your Appointment

Most platforms offer online scheduling with availability often within a few days. Choose a time when you can be in a private, quiet location with reliable internet access.

4. Attend Your Consultation

Be honest and thorough in sharing your experiences. The more information your provider has, the better they can tailor treatment to your needs.

5. Follow the Treatment Plan

If medication is prescribed:

• Take it exactly as directed
• Attend all follow-up appointments
• Report any side effects promptly
• Be patient—improvements may take several weeks
• Engage with recommended therapy or counseling

6. Stay Connected

Use your provider’s messaging features between appointments for non-urgent questions. Don’t hesitate to request an earlier follow-up if you’re experiencing concerning symptoms.

Conclusion: Accessible, Safe BED Treatment Is Within Reach

Telehealth has fundamentally transformed access to binge eating disorder treatment. In 2026, individuals across the United States can connect with qualified providers and access evidence-based medications like topiramate and bupropion without the barriers of geography, transportation, or scheduling constraints that often delay help-seeking.

The regulatory framework—both federal and state—supports this access for non-controlled medications while maintaining appropriate safety standards. Whether you’re in California, New York, Texas, or anywhere in between, legitimate telehealth options are available, combining the convenience of virtual care with the clinical rigor of traditional medical practice.

If you’re struggling with binge eating disorder, you don’t have to face it alone or wait months for an in-person appointment. Today’s telehealth platforms offer a pathway to evaluation, treatment, and ongoing support that fits into your life while prioritizing your safety and recovery.

Ready to take the first step toward recovery? Klarity Health connects you with licensed mental health providers who specialize in eating disorders. With flexible scheduling, transparent pricing for both insurance and self-pay patients, and comprehensive care that addresses your whole health, Klarity makes quality BED treatment accessible when and where you need it. Schedule your confidential consultation today and start your journey toward a healthier relationship with food.

Research Currency Statement

Verified as of: January 4, 2026

• DEA Rules Status: COVID-19 telehealth prescribing flexibilities remain in effect through December 31, 2026 (fourth extension). No federal in-person requirement exists for non-controlled medications—these were never subject to the Ryan Haight Act restrictions on telemedicine.

• States Verified: Researched 10+ key states (AL, CA, DE, FL, GA, NH, NY, TX, MI, WI, etc.) with latest information as of late 2025. State board sites and 2025 legislative updates were checked where available.

• Sources Newer Than 2024: 80%+ of sources are from 2025 (many late-2025) or updated to 2025. Older sources (2024) were used only when confirmed still accurate by newer references.

• Flagged for Follow-Up: Alabama and South Carolina NP scope changes (legislation was discussed in 2025 but final status unclear—assume no full independence yet pending confirmation). Monitor DEA’s pending final rule on telehealth prescribing (expected by end of 2026). Verify any temporary state waivers for expiration/extension beyond 2025.

Citations

1. U.S. Department of Health and Human Services. (2026, January). ‘DEA Extends Telemedicine Prescribing Flexibilities Through December 2026.’ Retrieved from https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Sheppard Mullin Richter & Hampton LLP. (2025, August). ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ Retrieved from https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

3. Center for Connected Health Policy. (2025). ‘State Telehealth Laws and Reimbursement Policies: Online Prescribing.’ Retrieved from https://www.cchpca.org/topic/online-prescribing/

4. Health Jobs Nationwide. (2025). ‘State-by-State Guide: Expanding Roles for PAs and NPs (Updated 2025).’ Retrieved from https://blog.healthjobsnationwide.com/state-by-state-guide-expanding-roles-for-pas-and-nps-updated-2025/

5. National Library of Medicine – DailyMed. ‘Bupropion Hydrochloride Extended-Release Tablets – FDA Label.’ Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1b69c253-4740-44b0-be63-6c20834540b6

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=patients%20to%20receive%20prescriptions%20for,while%20permanent%20rules%20are%20finalized
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=extended%20telemedicine%20prescribing%20waivers%20through,prescribing
• https://blog.healthjobsnationwide.com/state-by-state-guide-expanding-roles-for-pas-and-nps-updated-2025/#:~:text=Full%20practice%20authority%20legislation%20reached,12
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=coordination%20with%20the%20U,prescribing
• https://telehealth.hhs.gov/providers/telehealth-policy/prescribing-controlled-substances-via-telehealth#:~:text=The%20Drug%20Enforcement%20Administration%20,through%20December%2031%2C%202025
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Prior%20to%20the%202024%20waiver,access%2C%20and%20diversion%20control%20measures
• https://www.cchpca.org/topic/online-prescribing/#:~:text=If%20a%20physician%20or%20practice,resolution%2C%20the%20physician%20shall%20either
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=constitutes%20unprofessional%20conduct,the%20appropriate%20standard%20of%20care
• https://blog.healthjobsnationwide.com/state-by-state-guide-expanding-roles-for-pas-and-nps-updated-2025/#:~:text=California%20leads%20the%20most%20important,12